Slowly Expanding Lesions in Multiple Sclerosis: A Systematic Review and Meta-Analysis
Open Access
Abstract
Background: Slowly expanding lesions (SELs) have been introduced as a radiological marker of chronic active demyelination and smoldering inflammation. These lesions are recognized as indicators of disability worsening and brain atrophy in people with multiple sclerosis (PwMS). We aimed to provide an overview of the available evidence on the prevalence and clinical relevance of SELs in PwMS. Methods: PubMed, Embase, Scopus, and Web of Science were systematically searched up to 25 May 2025, to identify studies evaluating SELs in PwMS. Risk of bias was assessed using the Newcastle–Ottawa Scale. We conducted a thorough review to evaluate the clinical relevance of SELs in MS. Additionally, a meta-analysis was performed using R software to estimate the pooled prevalence of SELs in MS. Results: Twenty studies on 4970 PwMS met the inclusion criteria. Meta-analysis indicated that the pooled prevalence of SELs in PwMS was 57.1% (95% CI: 44.9% to 69.3%). Moreover, the systematic review showed that SELs were associated with chronic neuroinflammation, ongoing demyelination, disability, microstructural damage, and axonal degeneration. Intervention studies also indicated that the number and volume of SELs were decreased following the administration of disease-modifying therapies. Conclusions: SELs are revealed to affect around half of PwMS and are associated with disability and disease progression in MS. These results highlight the potential role of SELs as a critical radiomarker in MS. However, future studies are warranted to validate these preliminary findings.Keywords
This publication has 67 references indexed in Scilit:
- Longitudinal Multiparametric QuantitativeMRIEvaluation of Acute and Chronic Multiple Sclerosis Paramagnetic Rim LesionsJournal of Magnetic Resonance Imaging, 2024
- Knowledge mapping of disease-modifying therapy (DMT) in multiple sclerosis (MS): A bibliometrics analysisHeliyon, 2024
- Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple SclerosisJAMA Neurology, 2024
- Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis managementEBioMedicine, 2024
- Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple SclerosisJAMA Neurology, 2023
- Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosisJournal of Neurology, 2023
- Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple SclerosisJAMA Neurology, 2023
- Inflammatory intrathecal profiles and cortical damage in multiple sclerosisAnnals of Neurology, 2018
- Multiple sclerosis: New insights and trendsAsian Pacific Journal of Tropical Biomedicine, 2016
- A comparison of phase imaging and quantitative susceptibility mapping in the imaging of multiple sclerosis lesions at ultrahigh fieldMagnetic Resonance Materials in Physics, Biology and Medicine, 2016